AbbVie says that Elahere is the first and only folate receptor alpha (FRÉ‘)-directed antibody drug conjugate (ADC) medicine ...
The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.
AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...
NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancer; Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate st ...
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a ...
PLYMOUTH MEETING, Pa., Nov. 19, 2024 /PRNewswire/ -- The Institute for Safe Medication Practices (ISMP) is proud to announce ...
Trump Intends to Use Emergency Powers and the Military for Deportations Donald Trump addressed his plans for mass deportations in a social media post. He is expected to interview candidates for ...
Footage of a man being shoved into a wall by a police officer before being dragged through a front yard has been shared on social media, with SA Police confirming a formal complaint has been made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback